INTRODUCTION
Acute myeloid leukemia (AML) is one of the most common leukemias in adults. AML is generally regarded as a stem cell disease characterized by an accumulation of undifferentiated and functionally heterogeneous populations of cells [1, 2] . AML stem cells are CD34 positive cells; in addition they have been recognized as CD38 negative [3] . These CD34+CD38-cells have chemotherapy-resistant properties [4] and are therefore possibly responsible for the outgrowth of minimal residual disease (MRD), which may cause relapse. Treatment failure in AML may be caused by the presence of LSCs [5] . LSCs exist in a stem cell microenvironment, also known as a stem cell niche, in a quiescent state, which allows the LSCs to become chemo resistant [6] [7] .
To recognize and identify LSCs and their behavior that may play an important role in the approach of targeted therapy. LSCs are considered as CD34+CD38− population and often express CD123, CD44, or CD184, which are rarely expressed on normal hematopoietic stem cells and could be also potential therapeutic targets [8] [9] [10] [11] [12] . CD123, the interleukin-3 (IL-3) receptor-alpha subunit, is highly expressed on LSCs [13] . Permanent cure of acute AML by chemotherapy alone remains elusive for most patients because of the inability to eradicate effectively LSCs. By identification of LSC specific cell surface markers, we can distinguish them from normal hematopoietic stem cells, so that, helps effectively to develop therapies targeting them [14] . A better understanding of LSCs and their molecular biology will allow the design of more effective therapies [15] . Although advances in the treatment of AML have led to survival improvement for younger patients, but this is not true for elderly patients where about 70% of patients 65 years or older die of AML within one year.
The aim of the present study was to identify LSCs in patients with AML and their correlations with treatment outcomes namely remission status, disease free survival (DFS), and overall survival (OS).
RESULTS
The present study was carried out on 30 patients with denovo AML, 16 males and 14 females. Their ages ranged from 21 to 67 years with median age 46 years. Demographic, clinical and laboratory data of patients with AML were demonstrated in (Table 1, 2) .
The mean percentage of blast cells in BM of AML patients was 62.08± 4.14 with a range of (24 -95%) and in peripheral blood was 31.42±1.24 with a range of (11.3-53.3 (Table 2 ).
Twenty one of AML patients (70%) achieved complete remission (CR) after induction chemotherapy. while nine patients (30%) did not achieve complete remission (non -CR). When the demographic and hematological parameters among CR and non-CR groups were compared (Table 3) 
Survival analysis among the study group
The mean OS of the whole study patients was 20.03±1.22 months while the median OS was 21 months (95% CI=18.32-21.48) (Figure 1) , moreover, the mean DFS was 16.96±1.02 months and the median was 18 months (95% CI=8.8-11.6) ( Figure 2 ).
As shown in (Table 4 ) and ( Figures 3, 4) , the mean OS of AML patients with complete remission was significantly higher than those who failed to achieve complete remission (23.5±1.01 vs. 10±0.7, P<0.000) and the median was (24 vs. 12 months, respectively). Similarly, the mean DFS of AML patients with complete remission was significantly higher than those who failed to achieve complete remission (10.1±0.6 vs.19.9±0.9, P<0.000) and the median was (20 vs LSCs and DFS, also significant negative correlations between the same factors and OS implicating difficulty of salvage therapy or reinduction therapy to prolong survival in this group of AML patients, correlations couldn't be done between FAB type and survival (because of small number of patients in each type and different types of variables as FAB is categorical variable while survival is numeric one), as shown in (Table 5) .
DISCUSSION
LSCs are known by their ability to undergo selfrenewal and their capacity to differentiate [16, 17] . For clinical treatment and patient survival it is important to know which putative LSCs will survive therapy. In that respect it is important to realize that the CD34 + CD38 -compartment has been shown to be the most therapy resistant in vitro [18] .
In this study, we found that the mean proportion of CD34 + CD38
low/− LSCs was statistically significantly lower in patient with acute leukemia in CR compared to patients www.oncotarget.com with non-CR and this agreed with Hwang and colleague, who had demonstrated in a group of 54 AML patients, that the proportion of CD34 + CD38
low/− cells at diagnosis was significantly lower in patients achieving CR compared to patients who did not achieve CR [19] . Also our results were in agreement with the results of Wilson et al. and le Viseur et al. [20] [21] who reported that there was a correlation between CD38 expression and MRD status, so that AML patients with leukemic blasts expressing CD38 were more likely to be MRD positive.
In our study, we found that the percentage of CD34 + CD38 low/− CD123+ cells (CD123 + LSCs) was significantly lower in patient with AML with CR than in patients with non-CR and this result came in harmony with the study of Hwang et al., [19] who observed a somewhat higher level of CD123 expression on LSCs in the non-CR group and relapsed group. Also this agreed with Jin et al., who observed that the increased levels of CD123 + LSCs in AML patients were known to be associated with a high proportion of blasts and a low CR rate [22] .
The burden of LSCs in AML patients is considered a strong biomarker for clinical outcomes in AML [23] [24] .
LSCs frequency is associated with worse outcomes namely remission and survival [5] ; AML patients with greater than 3.5% of CD34 +
CD38
-LSCs show a median relapse free survival of 5.6 mo vs. 16 mo in those with a lower percentage of CD34 + CD38
-cells [5] . Our results were in agreement with the previous came in agreement with other studies [26] . This significant negative correlation between higher WBC counts and reduced OS and DFS could be explained partly by the fact that high WBC counts were associated with an increased risk of tumor lysis syndrome and leukostasis and both were considered oncologic emergencies and subsequently affected the prognosis of patients [27] . 
CD123
+ LSCs are predictive of poor EFS and OS [5, 29] , collectively our results were in concordance with these studies.
Generally, eradication of blasts can be achieved by systemic multi-agent chemotherapy. However given that LSCs contained within CD34 +
CD38
-CD123 + population in AML and difficulty to eradicate these malignant cells in this subgroup supports the hypothesis that in order to maintain complete remission after induction chemotherapy and to improve survival in AML patients, traditional chemotherapy targeting blasts should be combined with agents targeting LSCs.
With the poor prognosis of AML and only little improvements in treatment options, there is an imperative need for novel therapies, so therapies targeting LSC may offer a hope for prognostic improvement. In this regard, selection of the target highly expressed by LSCs and the timing of therapy may result in improved prognosis.
PATIENTS AND METHODS
In our study, we investigated 30 patients with newly diagnosed AML attending to South Egypt Cancer Institute, from May 2016 to October 2017. The study protocol followed the ethical guidelines of the 1975 Helsinki Declaration and was approved by the Ethical and Research committee of South Egypt Cancer Institute, Assiut University. An informed written consent in accordance was taken from all cases. Diagnosis of AML was achieved by morphologic, cytochemical, immunophenotypic and cytogenetic studies.
All patients were subjected to:
• Complete history taking, thorough physical and clinical examination.
• Complete blood count (CBC) including differential leukocyte count was done Using cell dyne 3500 automated cell counter (ABBOTT DIAGNOSTIC).
• Peripheral smear examination and bone marrow aspiration examination.
• Cytochemistry studies, such as myeloperoxidase, esterases, acid phosphatase and Periodic acid-Schiff.
• Immunophenotyping of leukemic cells was performed routinely in bone marrow using monoclonal antibodies that were used for diagnosing AML included: CD34. CD13, CD33, CD117, CD15 and intracellular myeloperoxidase, CD14, HLA-DR, CD41, CD61 and antiglycophorin A. All monoclonal antibodies were purchased from Becton Dickinson (BD) Bioscience, CA, USA.
• Flow cytometric detection of LSCs and their expression of CD123
• Induction chemotherapy after diagnosis given for those younger than 60 years was in the form of anthracycline 
Statistics
Data were presented as mean ±SE, percentages. For the association between quantitative variables and categorical dependant variables (remission, no remission) unpaired t-test test and Mann Whitney test were used, furthermore, Chi 2 test was used to assess the relations between 2 categorical variables (response and FAB subtype), Pearson correlation was used to study the magnitude of association between different prognostic factors and survival.
Regarding the analysis of OS, and DFS of our patients, for the whole study group survival curves were constructed by Kaplan-Meier method, for comparison of DFS, and OS between two unpaired groups (remission, no remission) log rank test was used and differences with P-value <0.05 being considered significant with 95% confidence interval (95% CI), P-value <0.01-0.001 was considered moderately significant, and P-value<0.001 was considered highly significant. www.oncotarget.com
The definitions used for calculation of survival followed the revised recommendations of the international working group for therapeutic studies [30] . OS was defined as the time interval between date of diagnosis and date of death or last follow up visit, while DFS was defined as the time interval between date of diagnosis and date of relapse, induction failure, or death from any other cause.
Remission was defined as the absence of signs and symptoms of the disease associated with normal CBC, and less than 5% blasts in BMA. Deviation from these criteria of remission was considered no remission. All data were analyzed using SPSS version 21.
CONCLUSIONS
Our study elucidated that the CD34 + CD38
low/− CD123 + phenotype is present in a significant proportion of AML patients and it may be responsible for resistance to traditional treatments, and high percentage of MRD that is translated into significantly high number of non CR, poor DFS, and OS.
